Pulling Together: Global Regulators Discuss Convergence On Biosimilars

Representatives From European, US, Japanese And Saudi Agencies Talk Streamlining

While the biosimilars industry has welcomed individual pockets of progress around regulatory streamlining, it is essential that approaches from global authorities move forward together if they are to have a meaningful impact on biosimilar development. At Medicines for Europe’s annual biosimilars conference, regulators from around the world talked about how their thinking is converging.

A panel of international regulators discussed convergence around biosimilar streamlining (Medicines for Europe)

More from Medicines for Europe

More from Policy & Regulation